Market capitalization | $7.45m |
Enterprise Value | $5.96m |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | 2.89 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-22.83m |
Cash position | $1.49m |
EPS (TTM) EPS | $-11.92 |
P/E forward | negative |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Genprex, Inc.:
1 Analyst has issued a forecast Genprex, Inc.:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.01 -0.01 |
50%
50%
|
|
EBITDA | -23 -23 |
28%
28%
|
EBIT (Operating Income) EBIT | -23 -23 |
28%
28%
|
Net Profit | -23 -23 |
28%
28%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.
Head office | United States |
CEO | Ryan Confer |
Employees | 26 |
Founded | 2009 |
Website | www.genprex.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.